Drugs / ABO2102
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06577532 | Sep 2024 → Dec 2026 expected | malignant pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07455617 | Mar 2026 → Jun 2029 expected | metastatic neoplasm | Suzhou Abogen Biosciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO2102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07455617 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA encoding mutant KRAS neoantigens” NCT06577532 ↗ |
| Route | Intramuscular | “administrated intramuscularly” NCT06577532 ↗ |